Benitec Biopharma Inc.
BNTC
$-0.76
Change (1 day)
$13.29
Year High
$2.69
Year Low
Categories
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc. (BNTC) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2024 | 229 K | -50,582,000 | 4.96 M | 52.21 M | 51.67 M |
| 2023 | -1,918,000 | 4.26 M | 4.46 M | 3.73 M | |
| 2022 | 3 K | -3,251,000 | 3.09 M | 5.97 M | 4.82 M |
| 2021 | 25 K | -19,556,000 | 1.37 M | 21.38 M | 20.61 M |
| 2020 | 59 K | -9,396,000 | 1.35 M | 11.59 M | 10.81 M |